Merck & Co., Inc. (MRK)
| Market Cap | 322.09B |
| Revenue (ttm) | 60.12B |
| Net Income (ttm) | 365.00M |
| Shares Out | 2.53B |
| EPS (ttm) | 0.14 |
| PE Ratio | 907.29 |
| Forward PE | 14.68 |
| Dividend | $3.08 (2.42%) |
| Ex-Dividend Date | Mar 14, 2024 |
| Volume | 2,732,536 |
| Open | 126.82 |
| Previous Close | 126.88 |
| Day's Range | 125.35 - 127.18 |
| 52-Week Range | 99.14 - 133.10 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 131.08 (+3.08%) |
| Earnings Date | Apr 25, 2024 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Variv... [Read more]
Financial Performance
In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $131.08, which is an increase of 3.08% from the latest price.
News
Higher Keytruda Sales To Drive Merck's Q1?
Merck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. We expect the company to post revenue of $15.2 billion and adjusted earnings of $1.97, slightly ahead of the street estimates.
Cramer's week ahead: Earnings from Tesla, Merck and Big Tech
CNBC's Jim Cramer said next week's PCE index report will be the real gauge of inflation.
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational...
Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.
Pfizer's patent expirations are great for humanity but terrible for investors. It's a common story across the drug industry.
Merck Foundation announced ‘‘Diabetes and Hypertension'' Media Recognition Awards 2024 for Asian Countries
MUMBAI, India--(BUSINESS WIRE)-- #Diabetes--Merck Foundation announced "Diabetes and Hypertension" Media Recognition Awards 2024 for Asian Countries.
Merck Foundation Announced "Diabetes and Hypertension" Media Recognition Awards 2024 for Latin American Countries
SAN JOSÉ, Costa Rica--(BUSINESS WIRE)-- #Diabetes--Merck Foundation announced "Diabetes and Hypertension" Media Recognition Awards 2024 for Latin American Countries.
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer.
Merck's Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment
CHICAGO--(BUSINESS WIRE)--Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, has secure...
Merck Continues the Fight against Schistosomiasis in a Storytelling Lab
ADDIS ABABA, Ethiopia--(BUSINESS WIRE)-- #BilharziaStorytellingLab--On March 22, 2024, Merck announced the winners of its third Bilharzia Storytelling Lab in Addis Ababa, Ethiopia.
After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
Given its attractive valuation, we believe Pfizer stock (NYSE: PFE) is a better pick than its peer — Merck stock (NYSE: MRK). MRK trades at a higher valuation multiple of 5.6x revenues vs.
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25.
Merck CEO on Winrevair Approval, Obesity Drug, Health Costs
Merck Chair and CEO Robert M. Davis discusses the US approval of Winrevair, a new treatment for a rare, dangerous form of high blood pressure.
European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck's a...
Stock Market Today: Dow Outperforms as Merck Hits New High
The S&P 500 and Dow Jones Industrial Average snapped three-day losing streaks as drugmaker Merck rallied.
Three-Stock Lunch: Tesla, Merck, and RH
Jerry Castellini, Castle Ark Management president and CIO, joins 'Power Lunch' to discuss Castellini's investing take on three stocks: Tesla, Merck, and RH.
MRK Rallies on Drug Approval & MRNA Researches Flu
Merck (MRK) rallies after FDA drug approval. Kevin Green discusses this as Merck receives FDA approval for drug Winrevair to treat pulmonary arterial hypertension.
FDA approves Merck treatment for lung disease, stock rises
The Food and Drug Administration has approved Winrevair, Merck's (MRK) latest drug to treat pulmonary arterial hypertension, a lung condition. Investors have been anxiously awaiting the approval as th...
Merck's stock rallies toward a record after FDA OKs arterial-hypertension drug
Shares of Merck & Co. Inc. rallied into record territory Wednesday, after the drug giant's treatment for pulmonary arterial hypertension, Winrevair, was approved by the U.S. Food and Drug Administrati...
FDA Approves Merck's WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves Merck's WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension.
Merck shares rise on FDA approval for Winrevair
Merck shares gain 5% to $131.90 in afterhours trading following approval of its new drug for a potentially fatal lung disease.
FDA approves Merck's drug for rare, deadly lung condition
The approval is a win for Merck, which is working to diversify its revenue stream as its blockbuster cancer drug Keytruda nears a loss of market exclusivity.
US FDA approves Merck's blood pressure therapy
The U.S. FDA on Tuesday approved Merck's treatment for adults with high blood pressure due to constriction of lung arteries, adding another potential blockbuster drug to the pharmaceutical giant's por...
Merck's $11.5 Billion Bet on Its Next Big Drug Finally Arrives
The newly approved drug, which treats potentially fatal pulmonary arterial hypertension, is estimated to ring up as much as $7.5 billion in yearly sales.
Merck combination treatment for lung cancer fails late-stage study
Merck said on Thursday a combination of its cancer drugs Keytruda and Lynparza failed to meet the main goals of a late-stage study evaluating it as an initial treatment for a type of lung cancer.
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-006 trial evaluating KEYTRUDA, Merck's an...